You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

Claims for Patent: 7,557,188

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 7,557,188

Title:	Methods of treating blood coagulation disorders using a pharmaceutical preparation comprising vWF propeptide
Abstract:	Described is a pharmaceutical preparation for treating blood coagulation disorders comprising an effective amount of vWF propeptide as well as a method for producing such a preparation.
Inventor(s):	Schwarz; Hans-Peter (Vienna, AT), Varadi; Katalin (Vienna, AT), Turecek; Peter (Klosterneuburg, AT), Hemker; Hendrik Coenraad (Maastricht, NL), Beguin; Suzette Lucette (Maastricht, NL)
Assignee:	Baxter Innovations GmbH (Vienna, AT)
Application Number:	11/218,406
Patent Claims:	1. A method of treating a blood coagulation disorder comprising the step of administering a pharmaceutical preparation comprising an effective amount of a molecule selected from the group consisting of vWF-propeptide (pp-vWF) and pro-vWF to a patient. 2. The method according to claim 1, wherein the blood coagulation disorder is selected from the group consisting of von Willebrand's disease, phenotypic hemophilia, hemophilia A and factor VIII inhibitors. 3. The method according to claim 1, wherein the pharmaceutical preparation further comprises an effective amount of a hemostasis protein selected from the group consisting of mature vWF, factor VIII, activated blood coagulation factors, blood factors with factor eight inhibitor bypassing (FEIB) activity and FEIBA. 4. A method according to claim 3, wherein pro-vWF is complexed to factor VIII. 5. The method according to claim 3, wherein the thrombosis risk of the patient is reduced when compared to patients treated with a pharmaceutical preparation not comprising an effective amount of a molecule selected from the group consisting of pp-vWF and pro-vWF. 6. The method according to claim 1, wherein the pharmaceutical preparation further comprises an effective amount of a platelet component selected from the group consisting of collagen, platelet glycoprotein, a platelet, fibrinogen, fibrin, or heparin. 7. A method of treating a patient at risk of a blood coagulation disorder comprising the step of administering a pharmaceutical preparation comprising an effective amount of a molecule selected from the group consisting of vWF propeptide (pp-vWF) and pro-vWF to a patient, wherein the blood coagulation disorder is selected from the group consisting of von Willebrand's disease, phenotypic hemophilia, hemophilia A and factor VIII inhibitors.

Details for Patent 7,557,188

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Baxalta Us Inc.	AUTOPLEX, FEIBA NF, FEIBA VH	anti-inhibitor coagulant complex	For Injection	101447	12/21/1979	⤷ Try a Trial	2017-05-28
Baxalta Us Inc.	AUTOPLEX, FEIBA NF, FEIBA VH	anti-inhibitor coagulant complex	For Injection	101447	07/31/2000	⤷ Try a Trial	2017-05-28
Baxalta Us Inc.	AUTOPLEX, FEIBA NF, FEIBA VH	anti-inhibitor coagulant complex	For Injection	101447	08/11/2005	⤷ Try a Trial	2017-05-28
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.